Plaque rupture, thrombosis, and therapeutic implications

Pathophysiology of Haemostasis and Thrombosis

Volumn 26, Issue , 1996, Pages 269-284

  Fuster, Valentin ^a   Badimon, JuanJose ^a   Chesebro, James H ^a   Fallon, John T ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Antithrombic strategies; Atheroscleric lesions; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CHOLESTEROL; HEPARIN; LOW DENSITY LIPOPROTEIN; WARFARIN;

ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL INJURY; CONFERENCE PAPER; HUMAN; PRIORITY JOURNAL; THROMBOSIS;

ANTICOAGULANTS; ARTERIOSCLEROSIS; ASPIRIN; CLINICAL TRIALS; CORONARY THROMBOSIS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; FIBRINOLYTIC AGENTS; HUMANS; LIPIDS; MODELS, BIOLOGICAL; PLATELET AGGREGATION INHIBITORS; RUPTURE, SPONTANEOUS; THROMBOEMBOLISM; THROMBOPLASTIN; WARFARIN;

EID: 0029903965     PISSN: 14248832     EISSN: 14248840     Source Type: Journal    
DOI: 10.1159/000217308     Document Type: Article

References (54)

1. Fuster V. Badimon L, Badimon JJ. Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992;326(5):310-318.
2. Ross R. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 1993;362(6423):801-809.
3. Fustcr V. Mechanisms leading to myocardial infarction: Insights from studies of vascular biology. Lewis A. Conner Memorial Lecture. Circulation 1994;90(4):2126-2146.
4. Fuster V. Gotto AM. Libby P. Loscalzo J. McGill H. Task Force L Pathogenesis of coronary disease: The biologic role of risk factors. J Am Coll Cardiol 1996;27(5):964-1047.
5. Stary HC. Chandler AB, Dinsmore RE. Fuster V. Glagov S. Insull W. Rosenfeld ME. Schwartz CJ. Wagner WD. Wissler RW. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis: A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 1995:92:1355-1374.
6. Steinberg D. Antioxidants and atherosclerosis. A current assessment. Circulation 1991:84(3): 1420-1425.
7. Navab M. Berlinger JA, Watson AD. Hama SY, Territo MC, Lusis AJ. Shih DM. Van Lenten BJ. Frank JS, Demer LL. Edwards PA, Fogelman AM. The yin and yang of oxidation in the development of fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler Thromb Vase Biol 1996:16:831-842.
8. Badimon L, Badimon JJ. Fuster V. Regression of atherosclerotic lesions by high density lipo protein plasma fractions in the cholesterol-fed rabbit. J Clin Invest 1990:85:1234-1241.
9. Moncada S. Gryglewski R, Bunting S. Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976;263(5579):663-665.
10. Furchgott RF. Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arte rial smooth muscle by acetylcholine. Nature 1980;288(5789):373-376.
11. Yanagisawa M, Kurihara H. Chimaera S. et al. A novel potent vasoconstrictor peptide produ ced by vascular endothelial cells. Nature 1988;332(6163):411-415.
12. Egashira K. Inou T. Hirooka Y. et al. Impaired coronary blood flow response to acetylcholine in patient with coronary risk factors and proximal atherosclerotic lesions. J Clin Invest 1993:93(1):29-37.
13. Reddy KG, Nair RN, Sheehan HM, Hodgson JM. Evidence that selective endothelial dys function may occur in the absence of angiographic or ultrasound atherosclerosis in patients with risk factors for atherosclerosis. J Am Coll Cardiol 1994;25(4):833-843.
14. Richardson PD. Davies MJ, Born GV. Influence of plaque configuration and stress distribu tion on fissuring of coronary atherosclerotic plaques. Lancet 1989;2(8669): 1462-1463.
15. Falk E. Shah PK. Fustcr V. Coronary plaque disruption. Circulation 1995;92:657-671.
16. Ambrose JA, Tannenbaum M, Alexpoulos D. et al. Angiographic progression of coronary artery disease and the development of myocardial infarction. Am Coll Cardiol 1988:12:56-62.
17. Little WC. Constantinescu M. Applegate RJ. et al. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-modcrate coronary artery disca se. Circulation 1988:78(5 Pi. 1): 1157-1166.
18. Davies MJ, Richardson PD. Woolf N. Katz DR. Mann J. Risk of thrombosis in human atherosclerotic plaques. Role of extracellular lipid, macrophage, and smooth muscle content. Br Heart J 1993;69(5):377-381.
19. Maclssac AL. Thomas JD. Topol EJ. Toward the quiescent coronary plaque. J Am Coll Cardiol 1993;22:1228-1241.
20. Moreno PR, Falk E. Palacios IF. Newell JB. Fuster V. Fallon JT. Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. Circulation 1994;90(2):775-778.
21. Shah PK, Falk E, Badimon JJ, Fernandez-Ortiz A, Mailhac A. Villareal-Levy G. Fallon JT. Regnstrom J. Fuster V. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation 1995;92:1565-1569.
22. Galis ZS, Sukhova GK. Lark MW, Libby P. Increased expression of matrix metalloproteinase and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994;94(6):2493-2503.
23. Galis ZS, Sukhova GK, Kranzhofer R. Clark S, Libby P. Macrophage foam cells from experi mental atheroma constituitively produce matrix-degrading protéinases. Proc Natl Acad Sci USA 1995:92(2):402-406.
24. DeWood MA, Spores J, Notske R, et al. Prevalance of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980;303(16):897-902.
25. Fernandez-Ortiz A. Badimon JJ. Falk E. Fuster V. Meyer B. Mailhac A. Weng D. Shah PK, Badimon LL. Characterization of the relative thrombogenicity of atherosclerotic plaque components: Implications for consequences of plaque rupture. J Am Coll Cardiol 1994:23:1562-1569.
26. Banner DW et al. The crystal structure of the complex of blood coagulation factor Villa with soluble tissue factor. Nature 1996:380:41-46.
27. Wilcox JN, Smith KM. Schwartz SM, Gordon D. Localization of tissue factor in normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 1989;86:2839-2843.
28. Toschi V, Gallo R. Lettino M. Fallon JT. Fernandez-Ortiz A. Badimon L. Chesebro JH, Nemerson Y. Fuster V. Badimon JJ. Tissue factor predicts the thrombogenicity of human atherosclerotic plaque components. Circulation 1995;(Abstr):1-112, 1996 (In press).
29. Murmur J DE. Thiruvikraman SV. Fyfc BS. Guha A. Sharma SH. Ambrose JH. Fallon JT. Nemerson Y. Taubman M. The identification of active tissue factor in human coronary atheroma. Circulation 1996 (In press).
30. Thiruvikraman SV. Guha A. Roboz J. Taubman MB. Nemerson Y. Fallon JT. In situ localiza tion of tissue factor in human atherosclerotic plaques by binding of digoxigerine labeled factors Vila and X. Lab Invest 1996; in press.
31. Moreno PR. Bernardi VH. Lopez-Cuellar J, Palacios IF. Gold HK. Nemerson Y. Fuster V, Fallon JT. Macrophages, smooth muscle cells and tissue factor in unstable angina: Implications for cell mediated thrombogenicity in acute coronary syndromes. J Am Coll Cardiol 1996;27(Suppl A):306A
32. Badimon JJ, Lettino M. Toschi V. Gallo R. Fallon JT. Nemerson Y. Badimon L. Chesebro JH. Fuster V. Inhibitory effects of TFPI on thrombus formation triggered by lipid-rich human atherosclerotic plaques. Circulation 1995; 92(Suppl I):1-693.
33. Blankenhorn DH. Hodis HN. George Lyman Duff Memorial Lecture. Arterial imaging and atherosclerosis reversal. Arterioscler Thromb 1994:14(2): 177-192.
34. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994:344(8934): 1383-1389.
35. The Cholesterol And Recurrent Events (CARE) Group of Investigators. American College of Cardiology Scientific Session, March. 1996.
36. Shepard J. Cobbe SM. Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995:333:1301-1307.
37. Brown BG, Zhao XO. Sacco DE, Albers JJ. Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993:87(6): 1781-1791.
38. Small DM. Progression and regression of atherosclerotic lesions. Insights from Lipid-Physical Biochemistry. Arteriosclerosis 1988;8:103-129.
39. Loree HM, Tobias BJ. Gibson LJ. Kamm RD, Small DM. Lee RT. Mechanical properties of model atherosclerotic lesion lipid p«., ol. Athero Thromb 1994;14:230-234.
40. Guyton JR. Klemp KF. Development of the atherosclerotic core region. Chemical and ultra structure analysis of microdissected atherosclerotic lesions from human aorta. Arterioscler Thromb 1994:14:1305-1314.
41. Toussaint J-F. Southern JF, Fuster V. Kantor HL. 13C-NMR spectroscopy of human atherosclerotic lesions: Relation between fatty acid saturation, cholcsteryl ester content, and luminal obstruction. Arterioscl Thromb 1994;14:1951-1957.
42. Fuster V, Dyken ML, Vokonas PS, Hennckens C. Aspirin as a therapeutic agent in cardiovascular disease. Circulation 1993;87:659-675.
43. Hirsh J. Fuster V. Guide to anticoagulant therapy. Part 1: Heparin. Circulation 1994;89:1449-1468.
44. Hirsh J. Fuster V. Guide to anticoagulant therapy. Part 2: Oral anticoagulants. Circulation 1994;89:1469-1480.
45. Antiplatelet Trialists’ Collaboration. Collaborative overview of randomized trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994;308:81-106.
46. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy-II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. Br Med J 1994:308:159-168.
47. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349-360.
48. Frcudenberger RS, Fuster V. In Cardiovascular Therapeutics: 1st Edition. T. Smith (Ed.) Saunders, 1996. Boston. MA (In press).
49. Smith P. Antithrombotic therapy in the chronic phase myocardial infarction. In: Fuster V. Verstraete M, eds. Thrombosis in Cardiovascular Disorders. Philadelphia, PA: WB Saunders; 1992:343-362.
50. Breddin D, Loew D. Lechner K, et al. The German-Austrian Aspirin Trial: A comparison of aspirin, placebo and phenprocoumon in secondary prevention of myocardial infarction. Circulation 1980:62:63.
51. The EPSIM Research Group. A controlled comparison of aspirin and oral anticoagulants in prevention of death after myocardial infarction. N Engl J Med 1982:307:701.
52. Meijer A, Verheug F, Werter C. Aspirin versus coumadin in the prevention of reocclusion and recurrent ischemia after successful thrombolysis: A prospective placebo-controlled angiographic study. Results of the APRICOT study. Circulation 1993:87:1524.
53. Cohen, M. Adams PC. Parry G. Xiong J. Chamberlin D. Wicrczorek I. Fox KAA, Chescbro JH. Strain J. Keller C. Kelly A. Lancaster G. Alii J. Kronmal R. Fuster V. Combination anli thrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users: Primary endpoint analysis from the ATACS trial. Circulation 1994;89:81-88.
54. Fuster V. Presented at The American College of Cardiology Scientific Sessions March. 1996.